Beranda › Kanker Endometrium › Maryland
Uji klinis Kanker Endometrium di Maryland
22 studi untuk Kanker Endometrium mencari peserta di lokasi di Maryland.
Kota di Maryland
Teks studi resmi (Bahasa Inggris)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Walter Reed National Military Medical Center, Bethesda
- National Institutes of Health Clinical Center, Bethesda
- dan 1 lainnya
Menerima pesertaFase 2
Semua usia · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05564377Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Menerima pesertaFase 3
Usia 18 ke atas · Wanita · Diperbarui 2 Okt 2026 · NCT07198074Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- National Institutes of Health Clinical Center, Bethesda
Menerima pesertaFase 2
Usia 18 hingga 72 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT01174121A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Johns Hopkins University, Baltimore
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06172478A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Baltimore
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT05123482Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
- Sinai Hospital, Baltimore
- William Kahlert Reg. Can. Ctr, Westminster
Menerima pesertaFase 3
Usia 18 ke atas · Wanita · Diperbarui 9 Sep 2026 · NCT07166094DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Research Site, Baltimore
- Research Site, Silver Spring
Menerima pesertaFase 3
Usia 18 ke atas · Wanita · Diperbarui 3 Sep 2026 · NCT06989112FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center, Baltimore
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT05919264A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- National Institutes of Health, Bethesda
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT05592626Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Maryland Oncology Hematology, Rockville
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Agu 2026 · NCT05579366A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Maryland Oncology Hematology - Primary, Columbia
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Jul 2026 · NCT04657068Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Research Site, Baltimore
- Research Site, Baltimore
- Research Site, Silver Spring
Menerima pesertaFase 3
Usia 18 ke atas · Wanita · Diperbarui 29 Jul 2026 · NCT07044336Integrated Cancer Repository for Cancer Research
- Northwest Hospital, Randallstown
- William E. Kahlert Regional Cancer Center, Westminster
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 19 hingga 110 · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT02012699Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- Frederick Health Hospital, Frederick
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT07327489Vaginal Cuff Brachytherapy Fractionation Study
- University of Maryland Medical Center (UMMC), Baltimore
Menerima pesertaFase 3
Usia 18 ke atas · Wanita · Diperbarui 22 Apr 2026 · NCT03785288Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
- National Institutes of Health Clinical Center, Bethesda
Menerima pesertaFase 1/2
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 9 Apr 2026 · NCT06253494Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Mar 2026 · NCT03968406Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
- Maryland Oncology Hematology, P.A., Brandywine
Menerima pesertaFase 2
Usia 18 ke atas · Wanita · Diperbarui 24 Des 2025 · NCT06463028A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Nov 2025 · NCT05902988SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Baltimore
- Massive Bio SYNERGY-AI site, Bethesda
- Massive Bio SYNERGY-AI site, Silver Spring
- dan 1 lainnya
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774BP1001-A in Patients With Advanced or Recurrent Solid Tumors
- Holy Cross Hospital, Silver Spring
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Mar 2025 · NCT04196257Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
- Maryland Oncology Hematology, P.A., Silver Spring
Menerima pesertaFase 2/3
Usia 18 ke atas · Wanita · Diperbarui 2 Mei 2024 · NCT05797831Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.